Delphine Labit is the Director of Research at Thryv Therapeutics, where she leads studies focused on the impact of SGK1 inhibitors in oncology and other therapeutic areas. Delphine joined Thryv in early 2022 and brings over 20 years of industry experience in scientific research. Her expertise includes cellular and pharmacodynamic small molecule research and bioanalytical analysis in a GLP environment. Delphine specializes in drug development for oncology, immunology, and other applications.

Before joining Thryv Therapeutics, Delphine served as Principal Investigator for immunogenicity assays at Altasciences, where she established the Cellular Biology Unit within the Ligand Binding Assay department. Prior to that, she spent 16 years at Aegera Therapeutics, contributing to the development of kinase inhibitors for B cell malignancies and small molecule inhibitors targeting Inhibitor of Apoptosis Proteins (IAPs).

Delphine holds an MSc in Applied Molecular Cytology from Montpellier II University and a Master’s in Genetics from Paris-Diderot University in France. Her extensive experience and dedication to advancing drug development make her a valuable asset to the Thryv team.